ALGS — Aligos Therapeutics Share News
0.000.00%
Last trade - 00:00- $29.85m
- -$0.47m
- $2.19m
Brief: Aligos Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results
Aligos Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Aligos Therapeutics Reprioritizes Of Nash & Covid Programs
U.S. RESEARCH ROUNDUP-RingCentral, Samsara, Wells Fargo & Co
Aligos Therapeutics gains on brokerage rating upgrades
Brief: Aligos Therapeutics On Track To Complete Phase 2-Enabling Activities In 2023 For ALG-055009
Brief: Aligos Therapeutics Initiates Dosing With Its Small Interfering RNA Drug Candidate, ALG-125755, In Subjects With Chronic Hepatitis B
Brief: Aligos Therapeutics Expects First-In-Human Studies In Coronavirus Therapeutic Program In H1 2023
Brief: Aligos Therapeutics Presents Clinical Data For Its Nash Program And Nonclinical Data For Its Chronic Hepatitis B Portfolio At AASLD's The Liver Meeting 2022
Brief: Aligos Therapeutics Presents Clinical Data For Its Capsid Assembly Modulator, ALG-000184, At AASLD's The Liver Meeting 2022
Aligos Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Aligos Therapeutics Reports Q3 2022 Financial Results
Aligos Therapeutics Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: Aligos Therapeutics Initiates Dosing In Healthy Volunteers With Sirna Drug Candidate ALG-125755
Brief: Aligos Therapeutics Inc Says It Files A Response To Complaint Of, And Counterclaims Against, Janssen Biopharma
Brief: Aligos Therapeutics Reports Recent Business Progress And Second Quarter 2022 Financial Results
Brief: Aligos Therapeutics Initiates 12-Week Dosing Cohort In Phase 1B Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184
Aligos Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
U.S. RESEARCH ROUNDUP- Bioatla, BRF, Tegna